vTv Therapeutics Inc (NASDAQ:VTVT) shares fell 7.6% on Thursday . The company traded as low as $1.56 and last traded at $1.59, 549,903 shares traded hands during mid-day trading. A decline of 33% from the average session volume of 826,383 shares. The stock had previously closed at $1.72.
A number of research firms have recently weighed in on VTVT. HC Wainwright restated a “buy” rating and issued a $5.00 price target on shares of vTv Therapeutics in a research note on Friday, August 16th. ValuEngine downgraded shares of vTv Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, September 4th. Northland Securities set a $8.00 price target on shares of vTv Therapeutics and gave the company a “buy” rating in a research note on Wednesday. Finally, Zacks Investment Research downgraded shares of vTv Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, August 21st.
The company’s 50-day simple moving average is $1.38 and its 200-day simple moving average is $1.53.
In related news, major shareholder Ronald O. Perelman acquired 50,000 shares of the business’s stock in a transaction that occurred on Thursday, August 22nd. The shares were bought at an average cost of $1.38 per share, with a total value of $69,000.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Ronald O. Perelman acquired 606,061 shares of the business’s stock in a transaction that occurred on Wednesday, September 18th. The stock was bought at an average cost of $1.65 per share, for a total transaction of $1,000,000.65. The disclosure for this purchase can be found here. Insiders purchased 811,061 shares of company stock valued at $1,273,751 over the last 90 days. 1.70% of the stock is currently owned by company insiders.
An institutional investor recently raised its position in vTv Therapeutics stock. BlackRock Inc. increased its stake in vTv Therapeutics Inc (NASDAQ:VTVT) by 25.7% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 65,031 shares of the biotechnology company’s stock after acquiring an additional 13,305 shares during the quarter. BlackRock Inc. owned about 0.12% of vTv Therapeutics worth $93,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 1.64% of the company’s stock.
vTv Therapeutics Company Profile (NASDAQ:VTVT)
vTv Therapeutics Inc, a clinical-stage biopharmaceutical company, discovers and develops orally administered small molecule drug candidates to fill unmet medical needs. The company is developing Azeliragon, an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase II/III clinical trials for the treatment of mild Alzheimer's disease.
Featured Article: What is a death cross?
Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.